Literature DB >> 8901674

Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction.

E K Weir1, H L Reeve, J M Huang, E Michelakis, D P Nelson, V Hampl, S L Archer.   

Abstract

BACKGROUND: The appetite suppressant aminorex fumarate is thought to have caused an epidemic of pulmonary hypertension in Europe in the 1960s. More recently, pulmonary hypertension has been described in some patients taking other amphetamine-like, anorexic agents: fenfluramine and its d-isomer, dexfenfluramine. No mechanism has been demonstrated that might account for the association between anorexic drugs and pulmonary hypertension. METHODS AND
RESULTS: Using the whole-cell, patch-clamp technique, we found that aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in smooth muscle cells taken from the small resistance pulmonary arteries of the rat lung. Dexfenfluramine causes reversible membrane depolarization in these cells. These actions are similar to those of hypoxia, which initiates pulmonary vasoconstriction by inhibiting a potassium current in pulmonary vascular smooth muscle. In the isolated, perfused rat lung, aminorex, fenfluramine, and dexfenfluramine induce a dose-related increase in perfusion pressure. When the production of endogenous NO is inhibited by N-nitro-L-arginine methyl ester, the pressor response to dexfenfluramine is greatly enhanced.
CONCLUSIONS: These observations indicate that anorexic agents, like hypoxia, can inhibit potassium current, cause membrane depolarization, and stimulate pulmonary vasoconstriction. They suggest one mechanism that could be responsible for initiating pulmonary hypertension in susceptible individuals. It is possible that susceptibility is the result of the reduced production of an endogenous vasodilator, such as NO, but this remains speculative.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901674     DOI: 10.1161/01.cir.94.9.2216

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

Review 1.  Primary pulmonary hypertension in childhood.

Authors:  S G Haworth
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

Review 2.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 3.  Pulmonary hypertension in the young.

Authors:  Sheila G Haworth
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

4.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

Review 5.  Acute oxygen-sensing mechanisms.

Authors:  E Kenneth Weir; José López-Barneo; Keith J Buckler; Stephen L Archer
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

6.  Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.

Authors:  Wai K P Wong; James A Knowles; Jane H Morse
Journal:  Am J Respir Cell Mol Biol       Date:  2005-07-07       Impact factor: 6.914

7.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

8.  Pulmonary hypertension: diagnosis and management.

Authors:  Michael D McGoon; Garvan C Kane
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

Review 9.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

10.  Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K+ channel in oxygen-sensitive pulmonary artery myocytes.

Authors:  A J Patel; M Lazdunski; E Honoré
Journal:  EMBO J       Date:  1997-11-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.